XENiOS® Will Seek Regulatory Approval for i-lung®
XENiOS®, a commercial-stage medical device company, announced today it expects to receive CE-marking for its i-lung® device within 18 months. XENIOS expects to launch i-lung® in 2017. Currently available devices lack durability and wearability. Additionally, the size of current systems restricts patient mobility and limits quality of life. i-lung represents an innovative and first-of-its-kind fully wearable artificial lung for long-term use in a hospital environment.
"The availability of i-lung will open the door to significant medical progress for respiratory support. For many patients in lung failure currently undergoing invasive mechanical ventilation, the use of i-lung is designed to avoid sedation and immobility, thus creating active, self-managed patients," said Georg Matheis, MD, Managing Director & Founder of XENIOS. "In addition, i-lung is designed to be used to bridge the waiting time for a donor organ (bridge-to-lung-transplant)."
"Of special note," added Juergen Boehm, MD, Managing Director of Xenios, "i-lung paves the way for XENiOS to continue development of a bioartificial lung for use by patients outside of a hospital environment analogous to current artificial heart protocols, which will represent a paradigm shift in the approach to long-term respiratory support."
i-lung is the result of the successful completion of the AmbuLung project, a three-year R&D consortium project funded by the European Union’s FP7 Program that developed the basis for i-lung, the world’s first-of-its-kind wearable artificial lung. In addition to XENiOS, the consortium included Fraunhofer IGB (Stuttgart, Germany); Imperial College of Science, Technology and Medicine (London, UK); and, the University of Florence (Italy).
"We are forever indebted to the vision and the work of Professor Dame Julia Polak, who passed away last year," said Dr. Matheis. "Julia and I co-founded the i-lung project, and because of her enormous contribution i-lung is now a reality, and a bioartificial next-gen of i-lung on the horizon." The author of some 1,000 original papers, 115 review articles and editor or author of 25 books, Julia Polak, MD, PhD, was one of the most widely cited researchers in her field, and had undergone a heart lung transplant. She served on several national and international tissue engineering and stem cell advisory panels, and was the European editor of the journal Tissue Engineering.
Funding for the commercialization of i-LUNG® has already been procured. XENIOS announced in September 2015 that it received an eight-figures cash infusion from existing investors, in part to fund CE-marking and launch of i-LUNG, led by ZFHN, one of the largest Single Family Offices in Germany investing in start-up companies.
XENiOS AG is a privately held medical technology company that is comprised of two product brands, novalung® and i–cor®, that run on a single XENiOS® console. The XENIOS platform is designed to provide at least four essential advantages with its minimally invasive lung and heart therapies: (1) patients are awake and mobile;(2) self-actuated patients facilitate improved outcomes; (3) there is no ventilator-associated lung injury or pneumonia; (4) additionally, the XENIOS platform maintains a physiologic natural pulse designed to protect the heart.
Most Popular Now
You might not want to depend on your smartphone app alone to help you avoid or achieve pregnancy, say the authors of a new study. A review of nearly 100 fertility awarene...Read more
What have the best brains of Europe come up with to improve health and wellbeing with the help of Information and Communication Technology (ICT)? This report offers an ...Read more
Royal Philips (NYSE: PHG, AEX: PHIA) has announced the successful start of a long-term strategic partnership with Servicio Andaluz de Salud (Andalusian Health Service, Sp...Read more
Wearable devices can give away your passwords, according to new research. In the paper "Friend or Foe?: Your Wearable Devices Reveal Your Personal PIN" scientists from Bi...Read more
A clinical trial testing mobile videoconferencing as a means for physicians to diagnose stroke patients while they're being transported to the hospital has found that a t...Read more
That's the question Drexel University researchers hope to answer with one of two new studies launching this month. They have developed a computer game and smartphone app ...Read more
Royal Philips (NYSE: PHG, AEX: PHIA) has signed a licensing agreement with Visiopharm to offer their breast cancer panel software algorithms  with Philips IntelliSite ...Read more
Scientists at the Montreal Neurological Institute and Hospital have used a powerful tool to better understand the progression of late-onset Alzheimer's disease (LOAD), id...Read more
Imagine a companion who is able to constantly motivate you, actively encourages you and changes your bad habits into healthy ones. A companion who is always present and w...Read more